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Abstract
Background: Gastric cancer is the second leading cause of cancer globally, and the mechanism of its pathogenesis
is still largely unknown. Recently, non-coding RNAs have been recognized to promote metastasis in various cancers,
including gastric cancer.
Methods: We found that metastasis associated lung adenocarcinoma transcript-1 (MALAT1) is upregulated in
gastric cancer tissue compared to adjacent normal tissue, as determined by microarray and subsequent qRT-PCR,
then investigated the impact of MALAT1 on apoptosis, cell proliferation, and the cell cycle to dissect the
carcinogenesis of gastric cancer, and examined mechanisms of invasion and metastasis. Expression of MALAT1 and
U6 was determined by SYBR qRT-PCR in nine-teen gastric cancer cell lines and fifty fresh samples of cancer tissue
and adjacent tissues. Downregulation of MALAT1 was accomplished with two different siRNAs. Cell proliferation
was determined after treatment with these siRNAs. FACS using PI/Annexin-V staining was carried out. To analyze
the invasiveness, a scratch wound-healing assay and a Matrigel invasion assay were performed. Cancer related gene
expression assay was done after transfection of siR- MALAT1.
Results: The expression of MALAT1 was significantly elevated in various gastric cancer cell lines and gastric cancer
tissues compared to normal cell lines and tissues (p < 0.01). siR-MALAT1 significantly reduced viable AGS cell
numbers and induced apoptosis (p < 0.05). Deep invasion of tumor (advanced T stages) was more common in the
high MALAT1-level group (p = 0.039). siR-MALAT1 significantly decreased AGS cell invasiveness and migration.
siR-MALAT1 reduced expression of snail and N-cadherin, and elevated E-cadherin. The Wnt/β-catenin related genes
were significantly decreased by transfection of siRNA MALAT1. MALAT1 is involved in gastric carcinogenesis via
inhibition of apoptosis and promotes invasiveness via the epithelial-to-mesenchymal transition.
Conclusions: In our study, we found that deregulation of MALAT1 could be involved in both tumorigenesis and
invasiveness in gastric cancer cells.
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Background
Gastric cancer is one of the major causes of death world-
wide; however, the mechanism of development and pro-
gression of gastric cancer is largely unknown [1, 2].
Recent studies have revealed that non-coding RNAs such
as microRNAs regulate epigenetic gene expression and
are dysregulated in some gastric cancers [3–6].
Long non-coding RNAs (lncRNAs) are a newly-
defined class of ncRNA with lengths greater than 200
nucleotides, and play important roles in biological pro-
cesses [5]. To date, some lncRNAs are known to be in-
volved in carcinogenesis and metastasis of various
cancers [3, 7–10]. We previously reported that HOTAIR
can regulate invasion and cell proliferation in gastric
cancer [11]. In consequence of this finding, we specu-
lated that there might be more lncRNAs involved in
gastric cancer development. lncRNA expression profiles
of certain diseases have been identified by microarray
and RNA seq [12, 13].
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Metastasis associated lung adenocarcinoma transcript-
1 (MALAT1) is known to be involved in alternative
splicing of pre-mRNAs by cell- or tissue-type-specifically
modulating serine/arginine (SR) splicing factors [14, 15].
In particular, MALAT1 (~8 kb) in the form of nuclear-
retained regulatory RNAs (nrRNAs) acts by interacting
with SR proteins and regulating their cellular level in
nuclear speckle domains in a phosphorylation-dependent
manner [16]. MALAT1 is significantly more highly
expressed in non–small cell lung carcinoma (NSCLC) pa-
tients and induces invasion, migration, and tumor growth
in many cancer types, including lung cancer, uterine
endometrial stromal sarcoma, colorectal cancer, and
hepatocellular carcinoma [17–21]. However, MALAT1
in gastric cancer has not been studied as of yet, and
functional and mechanistic studies of MALAT1 are in-
adequate and unclear [1].
In this study, we found changes in the expression of
MALAT1 in adjacent gastric normal and cancer tissues
through microarrays. Based on the microarray analysis,
we evaluated the impact of MALAT1 on apoptosis and
cell proliferation as indicators of carcinogenesis in gas-
tric cancer. We also investigated the clinical significance
of MALAT1 level as a predictor of severity of clinico-
pathological factors in patients with gastric cancer, and
tried to dissect MALAT1’s molecular mechanisms with
respect to invasion and metastasis in vitro.
Methods
Patients and tissue samples
Fifty fresh gastric cancer tissue and paired adjacent
gastric tissue samples were obtained from 50 patients
who underwent surgical resection for gastric cancer at
Severance Hospital, Yonsei University College of Medicine.
All samples were frozen in liquid nitrogen immediately
after resection and stored at −80 °C until use. The mean
age of patients was 60.7 (39–79) years and the male:female
ratio was 2.2:1.
Cell lines and cell culture
A total of 22 gastric cancer cell lines was used. The Yonsei
Cancer Center (YCC) series had obtained from Song-dang
Institute for Cancer Research, Yonsei University College
of Medicine. Cell lines were obtained from the Korean
Cell Line Bank (KCLB, SNU, Seoul, Korea) and the
American Type Culture Collection (ATCC, Rockville,
MD, USA). MKN 28, MKN 74, and AGS were cultured
in RPMI-1640 medium (Thermo Scientific, Rockford,
IL, USA) supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin and streptomycin solution. The
cells were maintained in a humidified atmosphere of
5% CO2 and 95% air at 37 °C.
Microarray and data analyses
New ncRNA microarray platforms from The University
of Texas MD Anderson Cancer Center that are not
commercially available were used in this study. This
array contains a collection of probes for various types of
non-coding RNAs (18,669 probes corresponding to 1338
human pre-miRNAs, 8980 probes corresponding to 660
mouse pre-miRNAs, 3320 probes corresponding to 484
ultraconserved genes, 16,314 pyknon probes, and 2275
probes corresponding to 192 other non-coding RNAs).
LncRNA Expression profiling analysis of the 3 paired sam-
ples including gastric cancer tissues and their matched
adjacent normal tissues was performed using an in-house
constructed microarray. Clinical characteristics of the three
gastric cancer patients included for non-coding microarray
are as follows: Two male and one female, each histological
grade are well-differentiated, moderately-differentiated,
and poorly differentiated adenocarcinoma. Their stages at
diagnosis were IB, IIB, and IIIA, respectively.
Bioinformatic analysis was performed using R (version
3.0.1) (http://www.r-project.org) and Bioconductor (http://
www.bioconductor.org/). The raw intensity for each probe
is the median feature pixel intensity with the median back-
ground subtracted. Setting an offset of 1 ensures that there
will be no negative values after log-transforming data. Data
was quantile normalized followed by log2 transformation.
Signals from probes measuring the same ncRNA were
averaged. A linear model was fitted to each gene and em-
pirical Bayes methods were used to obtain statistics. Statis-
tical significance was defined as a p-value less than 0.05.
Probes differentially expressed between samples were thus
identified. The analysis was performed using the functions
of the LIMMA library. Heatmaps were generated using
the heatplot function of the made4 library.
NanoString nCounter gene expression analysis
A total of 730 cancer-related human genes and 40 internal
reference genes were contained on cancer pathway panel
reporter and capture probe. For analysis, MKN28 cells
were transfected with siCT or siMALAT1. 100 ng of Total
RNA was used for hybridization, and analyzed on an
nCounter Digital Analyzer (NanoString Technologies,
Inc., Seattle, WA) according to the manufacturer’s instruc-
tions. Data quality control was implied using nSolver ana-
lysis software (NanoString Technologies). Reporter counts
were normalized to each sample using positive control
and housekeeping genes. The mean values were shown to
fold change or log transformation.
Small interfering RNA (siRNA) transfection
RNA interference-mediated knockdown of MALAT1 was
carried out using target siRNAs for MALAT1. MKN28,
MKN74, and AGS cells were transfected with three differ-
ent siRNAs for MALAT1 or stealth siRNA (Invitrogen,
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Carlsbad, CA, USA) using Lipofectamine 2000 (Invitrogen).
Target sequences for siRNAs targeting MALAT1 were:
siMALAT1-1, sense: 5’-GAUCCAUAAUCGGUUUCAA-3’,
antisense: 5’-UUGAAACCGAUUAUGGAUC-3’; siMALA
T1-2, sense: 5’-CACAGGGAAAGCGAGUGGUUGGUA
A-3’, antisense: 5’-UUACCAACCACUCGCUUUCCCUGU
G-3’; and MALAT1-3, sense: 5’-GCAGAGGCAUUUCAU
CCUU-3’, antisense: 5’-AAGGAUGAAAUGCCUCUGC-3’.
Total RNA extraction, reverse transcription, and
quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen). The total RNA was reverse transcribed with Super-
script II(Invitrogen) according to the manufacturer’s
instructions. The expression of MALAT1 was deter-
mined with qRT-PCR using the SYBR Green method
(Applied Biosystems Inc., Carlsbad, CA, USA). The level
of MALAT1 was normalized to the internal control, U6.
The Ct value was measured by the 2-ΔΔCt method. The
target sequences for MALAT1 and U6 were: MALAT1,
Forward: 5’-ACTGAATCCACTTCTGTGTAGC-3’ and Re-
verse: 5’-CGGAAGTAATTCAAGATCAAGAG-3’; and U6,
Forward: 5’-CTCGCTTCGGCAGCACA-3’ and Reverse:
5’-AACGCTTCAGGAATTTGCGT-3’.
Trans-well chamber-Matrigel invasion and migration assay
Invasion assays were performed with BD Biocoat
trans-well chambers (BD Biosciences, San Jose, CA,
USA) according to the manufacturer’s protocol.
MKN74 and AGS cells were transfected with each
siMALAT1 or siCT for 48 h. The transfected cells were
then plated in the upper chamber of the trans-well
chamber in RPMI 1640 Medium (Thermo Scientific)
without fetal bovine serum (FBS). The bottom of the
trans-well chamber was filled with RPMI 1640 with
10% FBS. The number of invading cells was counted
on a bright-field microscope. Five portions of the
membrane were randomly selected and the average
value of invading cells was calculated. For the migra-
tion assay, transfected MKN74, MKN28, and AGS cells
were replated. The cells were incubated until the for-
mation of an approximately 80–90% confluent mono-
layer. A P-20 micropipette tip was then used to mimic
a scratch wound. The ratio of migratory capacity was
determined by measuring the width of the scratch at 0
and 24 h by bright-field microscopy.
Western blotting
MKN74 and AGS cells were transfected with 100 nM
siMALAT1 or siCT. The cells were lysed in lysis buffer.
Cell lysates were resolved by 8–10% SDS-PAGE and
transferred to PVDF membranes (GE Healthcare, Piscat-
away, NJ, USA). After transfer, membranes were incubated
with primary antibodies in 5% BSA (Affymetrix, Inc. Santa
Clara, CA, USA) for 24 h at 4 °C. The primary antibodies
used were: mesenchymal marker N-cadherin (1:1000,
BD Biosciences), snail (1:1000, Cell Signaling Technol-
ogy), c-Myc (1:500, Santa Cruz), GSK-3β (1:200, Santa
Cruz), β-actin (1:5000, Bioworld Technology, Louis
Park, MN, USA) and β-catenin (1:500, Santa Cruz). To
visualize the target proteins, probed blots were incubated
in ECL solution (GenDEPOT, Barker, TX, USA) and
exposed to an Image Quant LAS 4000 bio-molecular
imager for 10 s to 5 min.
Cell proliferation and apoptosis
AGS and MKN28 cells were transfected with each siMA-
LAT1 or siCT and incubated in a time course ranging
from 0 to 96 h. Cell proliferation was measured by CellTi-
ter 96® AQueous One Solution Cell Proliferation Assay
(MTS assay, Promega, Madison, WI, USA). At various
time points, the cells were exposed to MTS reagent in the
dark for 1 h. The extent of the reaction was quantified
with a spectrophotometric plate reader set at 490 nm.
Propidium iodide and fluorescein isothiocyanate (FITC)-
Annexin V staining was carried out. The apoptotic ratio
was determined by flow cytometry (BD Biosciences).
Cell cycle analysis
MKN74 cells were transfected with siMALAT1 or siCT
and washed with 1X PBS (Thermo Scientific). After
washing, cells were fixed with 75% ethanol at −20 °C. for
24 h. The fixed cells were stained with propidium iodide
(Sigma, St. Louis, MO, USA). Cell cycle profiles were
analyzed via flow cytometry (BD Biosciences).
Soft agar colony formation
For analysis tumorigenecity in vitro, base and top agar-
ose were coated in 6-well cultured plates. 1.5 ml of 2X
RPMI1640 containing 1% Ultrapure Low Melting Point
Agarose (Gibco, Rockville, MD, USA) was added into
each well as base. After solidification, the transfected
cells were resuspended in 2X RPMI1640 UltraPure Low
Melting Point Agarose as top. The plates were main-
tained in a humidified atmosphere of 5% in air at 37 °C
for 3 weeks. Colonies were stained with 0.5% Crystal
Violet and measured under bright field microscopy.
Immunofluorescence
AGS cells were transfected with each siMALAT1 or
siCT, and fixed with 4% paraformaldehyde for 20 min.
After fixation, the cells were permeabilized with 0.3%
Triton X-100 in PBS for 30 min, and blocked with 5%
BSA in PBS for 1 h. After blocking, the cells were in-
cubated in β -catenin (1:200, Santa Cruz) overnight at
4 °C. the cells were treated with Cy2-conjugated anti
Mouse IgG (Jackson ImmunoResearch Laboratories)
for 1 h in the dark. The cells were mounted with DAPI
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vecta shield (Vector Laboratories, Burlingame, CA,
USA). The mounted cells were photographed using a
Zeiss LSM 700 confocal microscope (Carl Zeiss,
Oberkochen, Germany).
Statistical analysis
All data analysis of continuous and categorical variables
is presented as the mean ± standard error and the num-
ber of lesions with the percentage. Statistical tests used
Fig. 1 MALAT1 levels were measured in 47 of 50 patients with gastric cancer. Expression of MALAT1 was upregulated in gastric tissues
and cell lines. Supervised microarray analysis was done with respect to 192 “other non-coding RNAs” to find previously annotated
lncRNAs. Sample 7, sample 21, and sample 27 are paired with sample 8, sample 22, and sample 28, respectively. Up-regulated genes
are shown in red and down-regulated genes are shown in blue (a). The expression of MALAT1 was measured in 19 gastric cancer cell
lines, normal cell GES-1, RGM-1 and 5 normal adjacent tissues (b) and 47 fresh gastric cancer and paired adjacent gastric tissues (c). The
expression of MALAT1 was normalized to U6. Data shown represent the mean ± s.e.m. Asterisks represent a statistically significant
difference from the scrambled control (*P ≤ 0.05)
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to compare the measured results included the t-test, χ2
test, and Fisher’s exact test. The degree of expression of
MALAT1 in gastric cancer was categorized as low or
high, based on the median of MALAT1 expression.
Moreover, the Cox proportional hazard model was used
to adjust for possible confounding variables, including
sex, age, differentiation, and stage. A value of p < 0.05
was considered as a statistically significant difference for
comparisons between groups. All statistical procedures
were conducted using the statistical software SPSS for
Windows (version 18.0; SPSS Inc., Chicago, IL, USA).
Results
Long non-coding RNA MALAT1 is significantly upregu-
lated in gastric cancer
We analyzed the microarray results of the levels of 192
“other non-coding RNAs” to find previously annotated
lncRNAs with differential expressional patterns between
paired cancer and adjacent normal gastric tissues. Thirty
probes were upregulated more than 2-fold in paired gas-
tric cancer tissue relative to adjacent normal tissue,
while 29 probes were downregulated more than 2-fold
(Fig. 1a). Among these probes were examples such as
GAS5, HOTAIR, and MALAT1, which have been re-
ported to be involves in carcinogenesis. GAS5 has
already been reported to be associated with the occur-
rence of gastric cancer [22], and HOTAIR has also been
reported on by us [11]. We undertook to validate
MALAT1, which has not been previously reported as an
lncRNA involved in gastric adenocarcinoma.
Altered expression of MALAT1 in gastric cancer cell lines
and gastric cancer tissues
The level of MALAT1 was measured in 19 gastric can-
cer cell lines and compared to normal epithelial gastric
GES-1, 5 normal gastric tissues adjacent to cancer and
rat normal gastric surface mucous cell (RGM-1) (Fig. 1b).
The expression of MALAT1 was upregulated in gastric
cancer cell lines relative to levels in GES-1, 5 normal
gastric tissues and RGM.
MALAT1 levels were measured in 47 of 50 patients
with gastric cancer. The expression of MALAT1 was
significantly higher in gastric cancer tissues than in adja-
cent normal tissues. (Fig. 1c) (p > 0.05). Clinicopatho-
logic features were analyzed according to the level of
MALAT-1 expression (Table 1). Patients with higher
levels of MALAT-1 expression had greater depths of
invasion than did those with low levels of MALAT-1
(p = 0.039). In addition, tumors of patients in the
high-level MALAT-1 group tended toward more ad-
vanced TNM stage than did those in the low-level
MALAT-1 group (high vs. low; stage III, 80.8% vs.
19.2%, p = 0.505), but this did not reach statistical
significance. Patients with poorly differentiated histology
or signet ring cell carcinoma had higher expression of
MALAT1 compared to well to moderately differentiated
adenocarcinoma (p = 0.030). Age and sex, were not related
to MALAT-1 expression. We could not get good correl-
ation between overall survival and expression level of
MALT1 in this study (data not shown).
Inhibition of MALAT1 suppressed cell proliferation and
induced apoptosis
We employed RNAi-mediated knockdown of MALAT1
in AGS, MKN74, and MKN28 cells to explore mecha-
nisms of carcinogenesis. Three different siRNAs were
tested to knock down MALAT-1 in three different gas-
tric cancer cell lines (Fig. 2a). MALAT1 expression was
decreased by transfection with siMALAT1 compared with
levels in siCT-transfected cells. One of the MALAT1
Table 1 The relationship between MALAT1 expression and
clinicopathological feature of gastric cancer patients
Variables Number MALAT1 expression P-value
Low High
Age (years) 0.071
<65 24 3 (12.5) 21 (87.5)
≥65 23 8 (34.8) 15 (65.2)
Sex 0.725
Male 32 7 (21.9) 25 (78.1)
Female 15 4 (26.7) 11 (73.3)
Depth of tumor invasion 0.039
T1 ~ T2 10 5 (50.0) 5 (50.0)
T3 ~ T4 37 6 (16.2) 31 (83.8)
Lymph node metastasis 0.472
Absent 16 5 (31.3) 11 (68.8)
Present 31 6 (19.4) 25 (80.6)
Stage 0.505
I, II 21 6 (28.6) 15 (71.4)
III 26 5 (19.2) 21 (80.8)
Lauren’s classification 0.242
Intestinal 27 9 (33.3) 18 (66.7)
Diffuse 18 2 (11.1) 16 (88.9)
Mixed 2 0 (0.0) 2 (100.0)
Differentiation 0.030
Well to moderate 25 9 (36.0) 16 (64.0)
Poorly or signet ring cell 22 2 (9.1) 20 (90.9)
Serum CEA value >0.999
≤5 37 9 (24.3) 28 (75.7)
>5 10 2 (20.0) 8 (80.0)
Serum CA19-9 value 0.614
≤37 41 9 (22.0) 32 (78.0)
>37 6 2 (33.3) 4 (66.7)
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siRNA’s (siMALAT1-2) consistently decreased the level of
MALAT-1 to less than 50% of baseline in all three cell
lines. Next we performed an MTS assay to check viable
cell after transfection with siRNAs for MALAT1. In the
AGS and MKN74 cell lines, the three different siRNAs
significantly decreased the cell viability at both 24 and
72 h. The degree of reduction caused by siMALAT1-2
was greater than that by the other two siRNAs (Fig. 2b).
To analyze the effect of MALAT1 on cell proliferation,
PI/Annexin V staining was carried out. The apoptotic
ratio was significantly increased by siMALAT1-2 relative
to siCT in MKN74 and AGS cells (Fig. 3a). However,
knockdown of MALAT1 did not cause a significant
difference in MKN28 cells (data not shown); this result
indicates that certain phenotypic effects of MALAT1
may vary depending on the cell type.
Inhibition of MALAT1 induces arrest in S phase and
increased expression of RASSF6
As we found phenotypic effects in the form of cell
death by assaying cell proliferation and apoptotic ratio,
we then assayed defects in cell cycle progression, which
can also be involved in apoptosis. The S phase popula-
tion of cells was significantly increased in siMALAT1-
2-transfected cells, compared to those transfected with
siCT. The sub-G1 population, which is considered to
represent apoptotic cells, was significantly increased by
siMALAT1-2 transfection, compared to that in siCT-
transfected cells, in the MKN74 cell line (Fig. 3b).
When cell cycle progression was dysregulated by DNA
damage, mutation and tumorigenesis can occur. This S
phase arrest and increased sub-G1 population suggest
that deregulation of MALAT1 may contribute to apop-
tosis via perturbations of cell cycle progression.
To explore the effect of MALAT-1 on apoptosis and cell
cycle progression, we tested Ras association domain family
(RASSF) 6, which is known to stabilize p53, regulate apop-
tosis and the cell cycle, and function as a tumor suppressor
[23]. RASSF6 is also known to regulate the progression of
gastric carcinogenesis [24]. The mRNA level of RASSF6
was significantly increased by treatment with three differ-
ent siRNAs targeting MALAT1 compared with levels in
the siCT-transfected group (Fig. 3c). The protein level of
RASSF6 was also increased by treatment with siRNAs for
MALAT-1 (Fig. 3c). This finding suggests that MALAT-1
may impair RASSF6’s function as a tumor suppressor, and
thus promote gastric carcinogenesis. To monitor anchor-
age independent growth that measures cellular transform-
ation, we performed soft agar colony formation in vitro.
The clonogenic forming ability was decreased by siMA-
LAT1_2-transfected cells compared to siCT-transfected
cells (Fig. 3d). These results support that MALAT1 con-
tributes to tumorigenesis of gastric cancer cell.
Inhibition of MALAT1 decreased cell invasiveness and
migration
In our study, patients with high levels of MALAT1 had
deeper invasion and more advanced stages than did
Fig. 2 MALAT1 silencing suppressed cell proliferation. Gastric cancer cells were transfected with each siMALAT1 or siCT (a). Cell proliferation was
analyzed by MTS assay (b). The data shown in panels are representative of three independent experiments. Data shown represent the mean ±
s.e.m. Asterisks represent a statistically significant difference from the scrambled control (*P≤ 0.05; **P ≤ 0.01)
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Fig. 3 (See legend on next page.)
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patients with low expression of MALAT1. To determine
the relationship between advanced stage and MALAT1,
we explored the invasion and migration of gastric cancer
cells using siRNA for MALAT1. In a trans-well chamber-
Matrigel invasion assay, the invasion of MKN74 and AGS
cells was significantly suppressed by all three siMALAT1s
compared to that in the siCT-transfected group (Fig. 4a).
A wound-healing assay was performed using the AGS
cell line. All three siRNAs significantly reduced mi-
gration, which corresponded to the changes in the in-
vasion assay (Fig. 4b).
To further investigate the changes in invasion and mi-
gration induced by siMALAT1s, we performed western
blots using epithelial-to-mesenchymal transition (EMT)
markers. The mesenchymal markers, snail and N-
cadherin, were decreased by all three siMALAT1s com-
pared to levels in the siCT-transfected group (Fig. 4c). In
addition, expression of ZEB1, a mesenchymal marker, was
decreased by siMALAT1s in AGS cells (data not shown).
MALAT1 of high level is correlated with tumor invasion
and MALAT1 silencing regulates β-catenin signaling
Based on our clinical data, we focused on the role of
MALAT1 in tumor invasion. As the results, the expressions
of N-cadherin, β-catenin and snail were generally elevated in
cancer compared to adjacent normal tissues. Also, RASSF6
was shown decreased expression in cancer compared to ad-
jacent normal tissues (Fig. 5a). Among 5 paired samples,
snail, N-cadherin and β-catenin were high in cancer com-
pared to adjacent normal tissue in 5, 4 and 3 patients,
respectively. The level of RASSF6 was lower in cancer com-
pared to adjacent normal tissue in 4 out of 5 patients.
In accordance with these results, we carried out Nano-
String gene expression array to investigate the mechan-
ism. We found that expression of Wnt/beta-catenin
signaling and its related-genes were significant affected
by siMALAT1 compared to scramble (Supplement 1).
CTNNB1 and WNT were markedly down-regulated by
siMALAT1. The pattern of β-catenin and c-Myc were
confirmed to be decreased by siMALAT1 compared to
siCT in Western blot (Fig. 5b). The mRNA expression of
MMP9, Axin and β-catenin also was significantly de-
creased in siMALAT1 compared to scramble in both
AGS and MKN74 cells (Fig. 5c). According to these
results, we analyzed the morphological changes of β-
catenin by siMALAT1 in AGS cells using immunofluores-
cence. The nuclear localization of β-catenin was decreased
by siMALAT1 compared to siCT (Fig. 5d).
Discussion
It has been demonstrated that the long non-coding RNA
MALAT1 may regulate many biological processes, in-
cluding cancer development. We present here the novel
finding that MALAT1 is increased in gastric cancer
tissues compared to normal tissues according to micro-
array analysis. We confirmed that knockdown of MALAT1
induces apoptosis, arrest in S phase, and increased expres-
sion of the tumor suppressor, RASSF6. High expression of
MALAT1 in gastric cancer correlated with advanced T
stage, which was supported by the finding that Inhibition
of MALAT1 decreased cell invasiveness and migration.
Microarrays are useful tools for global analysis of gene
or protein content and expression. Recently a global ex-
pression profile of lncRNAs was analyzed by microarray
technique [25]. We used house-made non-coding RNA
expression arrays designed with probes targeting human
pre-miRNAs, mouse pre-miRNAs, ultraconserved genes,
pyknon probes, and other non-coding RNAs. We con-
centrated on 192 of these “other non-coding RNAs” to
find annotated lncRNAs in this study. Analysis and val-
idation of probes for UCR and pyknon will be conducted
in a subsequent study. We identified 59 probes that were
significantly differentially expressed between gastric can-
cer tissues and adjacent normal tissue. Of these, 30
lncRNAs were identified as consistently upregulated in
all three HCC groups, while the other 29 lncRNAs were
consistently downregulated. Among the upregulated
lncRNAs in the microarray, we had already validated
HOTAIR as having dysregulated expression in gastric
cancer in a previous report [11].
MALAT1 is one of several well-known lncRNAs in-
volved in many cancers, and our microarray results
showed significantly differential expression level in gas-
tric adjacent normal and cancer tissues. Based on these
results, MALAT1 may play a crucial role in gastric car-
cinogenesis and metastasis, as do HOTAIR and GAS-5.
MALAT1 was already known to be correlated with cell
proliferation and metastasis in a variety of cancers [19, 20,
26]. However, the functional role of MALAT1 in gastric
cancer has not yet been studied. Wang J et al. reported
that Serine/arginine-rich splicing factor 1 (SRSF1) down-
regulated Malat1 expression by enhancing RNA decay and
inhibiting YAP activity in a promoter context-dependent
manner in liver cancer [21]. We checked the relationship
between SRSF1 and MALAT1 in gastric cancer cell lines
(data not shown). We further explored whether MALAT1
could induce the constitutively active ΔRon isoform by
(See figure on previous page.)
Fig. 3 MALAT1 silencing induced apoptosis and cell cycle arrest. AGS and MKN74 cells were transfected with siMALAT1 or siCT, and apoptosis was
detected by PI/Annexin V staining (a). Cell cycle arrest was analyzed by PI staining (b). The increased expression of RASSF6 by qRT-PCR and western blot
(c). The decreased colony forming rate by siMALAT1_2 compared to siCT (d). The data shown in the panels are representative of three independent
experiments. Data shown represent the mean ± s.e.m. Asterisks represent a statistically significant difference from the scrambled control (*P≤ 0.05)
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inducing alternative splicing of Ron, which is involved in
cell dissociation, motility, and matrix invasion (data not
shown). Next, we tried to elucidate how MALAT1 acts in
gastric carcinogenesis through validation of some of its
targets that are tumor suppressor genes. In particular, the
metastasis-associated target gene, RASSF6, a member of
the RAS-association domain family, is downregulated in
gastric cancer, and its expression was upregulated by
Fig. 4 MALAT1 silencing inhibited cell invasiveness and the expression of EMT markers. AGS and MKN74 cells were transfected with siMALAT1 or
siCT and cell invasiveness was measured by trans-well chamber assay (a). Wound-healing assays were performed (b). Levels of the EMT markers,
N-cadherin and snail, were measured in AGS cells (c). Data are the mean of three independent experiments ± s.e.m. Asterisks represent a statistically
significant difference from the scrambled control (*P≤ 0.05; **P≤ 0.01)
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Fig. 5 (See legend on next page.)
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MALAT1 silencing, as revealed by genome-wide gene
expression analysis [17, 24]. In our study, knockdown of
MALAT1 induced increases in mRNA and protein levels
of RASSF6 in AGS cells. It has previously been reported
that expression of RASSF6 is correlated with invasion,
lymph node metastasis, and advanced clinical stage in
human gastric cancer [24].
Based on our results, expression of MALAT1 affects
apoptosis and cell cycle progression, correlating with
changes in cellular proliferation. Some of the gastric
cancer cell lines, AGS and MKN74, showed significantly
lessened cellular proliferation 48 h after treatment with
siMALAT1, leading to an increased apoptotic ratio and
S phase arrest corresponding with a decreased G0/G1
phase population. Wang J et al. reported an increased
population in the G0/G1 phase of the cell cycle by
propidium iodide staining. We observed an S phase
arrest in MKN74 cells, unlike Wang J et al. These results
indicated that even though the gastric cancer cells were
conspecific, lncRNAs act at a specific time during devel-
opment. Furthermore, we showed that clonogenic form-
ing ability was repressed by siMALAT1. The ability of
transformed cells under anchorage-independent growth is
important characteristic of carcinogenesis. This result
supports that MALAT1 has contributed to tumorigenesis
in gastric cancer cell.
In our study, dysregulation of MALAT1 was clearly
shown to affect the epithelial-to-mesenchymal transition
(EMT) through invasion and migration results. MALAT1
plays a role as a predictive marker for metastasis via the
EMT pathway, and its most important regulatory motif is
in its 3’ end (6918 nt- 8841 nt), which promotes invasion,
migration, and cell proliferation [15]. One study has indi-
cated that downregulation of MALAT1 inhibits metastasis
through regulation of CTHRC1, CCT4, HMMR, and
ROD1 [19]. Furthermore, we showed decreased migratory
capacity and invasiveness following MALAT1 silencing,
and found decreased expression of the mesenchymal
markers, N-cadherin and snail, which are major factors
that regulate the EMT in gastric cancer cells. In our gene
expression array to investigate comprehensive mechanism
of MALAT1 in gastric cancer, WNT/β-catenin signaling
was affected by knock down of MALAT1. WNT/β-ca-
tenin signaling was considered to be correlated with
tumor invasion in gastric cancer cell. The level of β-
catenin in both mRNA and protein was down-regulated
by knock down of MALAT1 in our study. The knock
down of MALAT1 altered nuclear translocation of β-
catenin. MALAT1 mediated-Wnt/β-catenin regulation
has reported in oral squamous, esophageal squamous cells
and colorectal cancer [27–29] but did not report in gastric
cancer yet.
This study had some limitations. The first limitation is
the small sample size. The small sample size makes diffi-
cult to determine exact impact of MALAT1 on patient’s
survival in this study.
In summary, we found that deregulation of MALAT1 is
involved in carcinogenesis and metastasis of gastric can-
cer. Although the exact mechanism thereof is not known,
it is related to the alteration of RASSF6 and β-catenin
caused by MALAT1. These findings suggest that gastric
cancers share the same pathogenic pathway of MALAT1
in carcinogenesis as do lung, esophageal, brain, pancreatic,
prostate, and liver cancer [17, 19, 30–32]. Our findings
highlight the interaction among the lncRNA, MALAT1,
RASSF6 and β-catenin during tumorigenesis and progres-
sion of gastric cancer.
Conclusions
In our study, we have demonstrated that lncRNA MALAT1
regulates proliferation and metastasis in gastric cancer cells.
Based on the microarray and gene expression results, we
provide the evidence that the change of the phenotype by
MALAT1 silencing is associated with the alteration of
RASSF6 and β-catenin at transcriptional level. Conse-
quently, lncRNA MALAT1 could be a new biomarker that
being therapeutic target for diagnosis of gastric cancer.
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